Advanced

The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer

Kashyap, Vasundhra; Ahmad, Shafqat LU ; Nilsson, Emeli M.; Helczynski, Leszek LU ; Kenna, Sinead; Persson, Jenny L LU ; Gudas, Lorraine J. and Mongan, Nigel P. (2013) In Molecular Oncology 7(3). p.555-566
Abstract
Recurrent prostate cancer remains a major clinical challenge. The lysine specific demethylase-1 (LSD1/KDM1A), together with the JmjC domain-containing JMJD2A and JMJD2C proteins, have emerged as critical regulators of histone lysine methylation. The LSD1-JMJD2 complex functions as a transcriptional co-regulator of hormone activated androgen and estrogen receptors at specific gene promoters. LSD1 also regulates DNA methylation and p53 function. LSD1 is overexpressed in numerous cancers including prostate cancer through an unknown mechanism. We investigated expression of the LSD1 and JMJD2A in malignant human prostate specimens. We correlated LSD1 and JMJD2A expression with known mediators of prostate cancer progression: VEGF-A and cyclin... (More)
Recurrent prostate cancer remains a major clinical challenge. The lysine specific demethylase-1 (LSD1/KDM1A), together with the JmjC domain-containing JMJD2A and JMJD2C proteins, have emerged as critical regulators of histone lysine methylation. The LSD1-JMJD2 complex functions as a transcriptional co-regulator of hormone activated androgen and estrogen receptors at specific gene promoters. LSD1 also regulates DNA methylation and p53 function. LSD1 is overexpressed in numerous cancers including prostate cancer through an unknown mechanism. We investigated expression of the LSD1 and JMJD2A in malignant human prostate specimens. We correlated LSD1 and JMJD2A expression with known mediators of prostate cancer progression: VEGF-A and cyclin A1. We show that elevated expression of LSD1, but not JMJD2A, correlates with prostate cancer recurrence and with increased VEGF-A expression. We show that functional depletion of LSD1 expression using siRNA in prostate cancer cells decreases VEGF-A and blocks androgen induced VEGF-A, PSA and Tmprss2 expression. We demonstrate that pharmacological inhibition of LSD1 reduces proliferation of both androgen dependent (LnCaP) and independent cell lines (LnCaP: C42, PC3). We show a direct mechanistic link between LSD1 overexpression and increased activity of pro-angiogenic pathways. New therapies targeting LSD1 activity should be useful in the treatment of hormone dependent and independent prostate cancer. (C) 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Epigenetic, Biomarker, Urological, Angiogenesis, Chromatin, Recurrence
in
Molecular Oncology
volume
7
issue
3
pages
555 - 566
publisher
Elsevier
external identifiers
  • wos:000321233400022
  • scopus:84878108124
ISSN
1574-7891
DOI
10.1016/j.molonc.2013.01.003
language
English
LU publication?
yes
id
58b696ca-c315-4522-b6ba-25716a9d1e95 (old id 3979839)
date added to LUP
2013-09-02 07:29:30
date last changed
2019-02-17 03:08:39
@article{58b696ca-c315-4522-b6ba-25716a9d1e95,
  abstract     = {Recurrent prostate cancer remains a major clinical challenge. The lysine specific demethylase-1 (LSD1/KDM1A), together with the JmjC domain-containing JMJD2A and JMJD2C proteins, have emerged as critical regulators of histone lysine methylation. The LSD1-JMJD2 complex functions as a transcriptional co-regulator of hormone activated androgen and estrogen receptors at specific gene promoters. LSD1 also regulates DNA methylation and p53 function. LSD1 is overexpressed in numerous cancers including prostate cancer through an unknown mechanism. We investigated expression of the LSD1 and JMJD2A in malignant human prostate specimens. We correlated LSD1 and JMJD2A expression with known mediators of prostate cancer progression: VEGF-A and cyclin A1. We show that elevated expression of LSD1, but not JMJD2A, correlates with prostate cancer recurrence and with increased VEGF-A expression. We show that functional depletion of LSD1 expression using siRNA in prostate cancer cells decreases VEGF-A and blocks androgen induced VEGF-A, PSA and Tmprss2 expression. We demonstrate that pharmacological inhibition of LSD1 reduces proliferation of both androgen dependent (LnCaP) and independent cell lines (LnCaP: C42, PC3). We show a direct mechanistic link between LSD1 overexpression and increased activity of pro-angiogenic pathways. New therapies targeting LSD1 activity should be useful in the treatment of hormone dependent and independent prostate cancer. (C) 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.},
  author       = {Kashyap, Vasundhra and Ahmad, Shafqat and Nilsson, Emeli M. and Helczynski, Leszek and Kenna, Sinead and Persson, Jenny L and Gudas, Lorraine J. and Mongan, Nigel P.},
  issn         = {1574-7891},
  keyword      = {Epigenetic,Biomarker,Urological,Angiogenesis,Chromatin,Recurrence},
  language     = {eng},
  number       = {3},
  pages        = {555--566},
  publisher    = {Elsevier},
  series       = {Molecular Oncology},
  title        = {The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer},
  url          = {http://dx.doi.org/10.1016/j.molonc.2013.01.003},
  volume       = {7},
  year         = {2013},
}